Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.81 |
| ▸ | PIM1 | P11309 | 11/20 | 0.59 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.59 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17967624 | 0.90 | MAPT (1.00) | MAPTPIM1PIM3PIM2CHEK1 | |
| SCHEMBL12666733 | 0.83 | CHEK1 (0.69) | MAPTPIM1PIM3PIM2CHEK1 | |
| SCHEMBL473684 | 0.81 | CHEK1 (0.58) | MAPTPIM1PIM3PIM2CHEK1 | |
| SCHEMBL473761 | 0.80 | PIM1 (0.61) | MAPTPIM1PIM3PIM2CHEK1 | |
| SCHEMBL1561286 | 0.79 | CHEK1 (0.56) | MAPTPIM1PIM3PIM2CHEK1 | |
| SCHEMBL1979380 | 0.79 | PIM1 (0.58) | MAPTPIM1PIM3PIM2CHEK1 | |
| SCHEMBL18440826 | 0.78 | CLK2 (0.70) | MAPTPIM1PIM3PIM2 | |
| SCHEMBL17592016 | 0.77 | PIM1 (0.65) | MAPTPIM1PIM3PIM2 | |
| SCHEMBL473670 | 0.77 | PIM1 (0.52) | MAPTPIM1PIM3PIM2CHEK1 | |
| SCHEMBL1560490 | 0.76 | MAPT (0.53) | MAPTPIM1PIM3PIM2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | claimed |
| EP-2303882-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2011-04-06 | — | — | EP | claimed |
| WO-2009150381-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | claimed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| EP-2303882-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009150381-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | MAPT 4868/4885PIM1 2969/4885PIM3 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.